The UK biotechnology sector's representative group has welcomed the decision by the House of Commons to pass the Human Fertilization and Embryology Bill, with minor amendments through the report stage and its third reading.
Aisling Burnand, the BioIndustry Association's chief executive, said: "the legislation was debated widely and at length throughout its passage through the House of Commons which has contributed to the development of a comprehensive piece of legislation." She added: "this Bill will help to enable the bioscience sector in the UK to continue to develop and grow. The research permitted by this Bill will be used to develop the techniques required for the production of stem cells, which could prove to be the source of treatments for diseases such as muscular dystrophy, Parkinson's and motor neurone disease."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze